Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis

Journal of Rheumatology

Volumn 32, Issue 5, 2005, Pages 935-942

  Kimura, Yukiko ^a   Pinho, Paulo ^a   Walco, Gary ^a   Higgins, Gloria ^b   Hummell, Donna ^c   Szer, Ilona ^d   Henrickson, Michael ^e   Watcher, Sandra ^f   Reiff, Andreas ^f  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^b Children's Hospital

^c VANDERBILT UNIVERSITY   (United States)

^d RADY CHILDREN'S HOSPITAL   (United States)

^e CHILDREN S HOSPITAL CENTRAL CALIFORNIA   (United States)

^f CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

Anti tumor necrosis factor therapy; Etanercept; Juvenile rheumatoid arthritis; Systemic onset

Indexed keywords

ACUTE PHASE PROTEIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE;

ADOLESCENT; ALLERGIC DISEASE; ARTICLE; CHILD; COHORT ANALYSIS; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERCALCIURIA; IMMUNOPATHOLOGY; INFANT; INFECTION; INJECTION SITE REACTION; JUVENILE RHEUMATOID ARTHRITIS; MACROPHAGE ACTIVATION SYNDROME; MAJOR CLINICAL STUDY; MALE; MYALGIA; NEPHROLITHIASIS; PRIORITY JOURNAL; QUESTIONNAIRE; SYNDROME; SYSTEMIC ONSET JUVENILE RHEUMATOID ARTHRITIS; URTICARIA;

ADOLESCENT; ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULIN G; INFANT; MALE; METHOTREXATE; PREDNISONE; QUESTIONNAIRES; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 18744366356     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Petty RE, Cassidy JR. The juvenile idiopathic arthritides and juvenile rheumatoid arthritis. In: Cassidy JR, Petty RE, editors. Textbook of pediatric rheumatology. 4th ed. Philadelphia: W.B. Saunders; 2001:214-321.
2. Calabro JJ, Holgersson WB, Sonpal GM, Khoury MI. Juvenile rheumatoid arthritis: a general survey of 100 patients observed for 15 years. Semin Arthritis Rheum 1976;5:257-98.
3. Lomater C, Gerloni V, Gattinara M, Mazzotti J, Cimaz R, Fantini F. Systemic onset juvenile rheumatoid arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J Rheumatol 2000;27:491-6.
4. Wallace CA, Levinson JE. Juvenile rheumatoid arthritis: outcome and treatment for the 1990's. Rheum Dis Clin North Am 1991;17:891-905.
5. Ansell BM, Wood PN. Prognosis in juvenile chronic polyarthritis. Clin Rheum Dis 1976;2:397-412.
6. Hafner R, Truckenbrodt H. Course and prognosis of systemic juvenile chronic arthritis - retrospective study of 187 patients [German]. Klin Padiatr 1986;198:401-7.
7. Ilowite NT. Current treatment of juvenile rheumatoid arthritis. Pediatrics 2002;109:109-15.
8. Reiff A, Rawlings E, Shaham B, Franke E, Bernstein B. Cyclosporine: a safe and effective alternative in the treatment of recalcitrant juvenile rheumatoid arthritis (JRA) and juvenile dermatomyositis. J Rheumatol 1997;24:2436-43.
9. Gerloni V, Cimaz R, Gattinara M, Arnoildi C, Pontikaki I, Fantini F. Efficacy and safety profile of cyclosporine A in the treatment of juvenile chronic (idiopathic) arthritis. Rheumatology Oxford 2001;20:907-13.
10. Wallace CA, Sherry DD. Trial of intravenous pulse cyclophosphamide and methylprednisolone in the treatment of severe systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 1997;40:1852-5.
11. Lehman TJ, Striegal KH, Onel KB. Thalidomide therapy for recalcitrant systemic onset juvenile rheumatoid arthritis. J Pediatr 2002;140:125-7.
12. Murray KJ, Lovell DJ. Advanced therapy for juvenile arthritis. Best Pract Res Clin Rheumatol 2002;16:361-78.
13. Kimura Y, Imundo L, Li S. High dose infliximab in the treatment of resistant systemic juvenile rheumatoid arthritis [abstract]. Arthritis Rheum 2001;44 Suppl:S272.
14. Wulffraat NM, Sander LA, Kuis W. Autologous hemopoietic stem-cell transplantation for children with refractory autoimmune disease. Curr Rheumatol Rep 2000;2:316-23.
15. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000;342:763-9.
16. Lovell DJ, Giannini EH, Reiff A, et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis; interim results from an ongoing multi-center, open-label, extended treatment trial. Arthritis Rheum 2003;48:218-26.
17. Quartier P, Taupin P, Bourdeaut F, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003;48:1093-101.
18. Higgins GC, Jones K, Rennenbohn RM. Variable response of systemic juvenile rheumatoid arthritis to etanercept [abstract]. Arthritis Rheum 2000;43 Suppl:S257.
19. ten Cate R, van Suijlekom-Smit LW, Brinkman DM, et al. Etanercept in four children with therapy-resistant systemic juvenile idiopathic arthritis. Rheumatology Oxford 2002;41:228-9.
20. Husni ME, Maier AL, Mease PJ, et al. Etanercept in the treatment of adult patients with Still's disease. Arthritis Rheum 2002;46:1171-6.
21. Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child 2001;85:421-6.
22. Stephan JL, Kone-Paut I, Galambrun C, Mouy R, Bader-Meunier B, Prieur AM. Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. Rheumatology Oxford 2001;40:1285-92.
23. Jacobs JC, Gorin LJ, Hannissian AS, Simon JL, Smithwick EM, Sullivan D. Consumption coagulopathy after gold therapy for JRA. J Pediatr 1984;105:674-5.
24. Barash J, Cooper M, Tauber Z. Hepatic, cutaneous and hematologic manifestations in juvenile chronic arthritis. Clin Exp Rheumatol 1991;9:541-3.
25. Prahalad S, Bove KE, Dickens D, Lovell DJ, Grom AA. Etanercept in the treatment of macrophage activation syndrome. J Rheumatol 2001;28:2120-4.
26. Ramana TV, Schneider R. Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J Rheumatol 2003;30:401-3.
27. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9.
28. Klareskog L, van der Heijde D, de Jager JP, et al, for TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
29. Lepore L, Pennesi M, Saletta S, Perticarari S, Presani G, Prodani M. Study of IL-2, IL-6, TNF-alpha, IF-gamma and delta in the serum and synovial fluid of patients with juvenile chronic arthritis. Clin Exp Rheumatol 1994;12:561-5.
30. Mangge H, Schauenstein K. Cytokines in juvenile rheumatoid arthritis (JRA). Cytokine 1998;10:471-80.
31. Madson KL, Moore TL, Lawrence JM, Osborn TG. Cytokine levels in serum and synovial fluid of patients with juvenile rheumatoid arthritis. J Rheumatol 1994;21:2359-69.
32. de Benedetti F, Massa M, Robbioni P, et al. Correlation of serum IL-6 levels with joint involvement and thrombocytosis in systemic juvenile chronic arthritis. Arthritis Rheum 1991;34:1158-63.
33. Prieur AM, Roux-Lombard P, Dayer JM. Dynamics of fever and the cytokine network in systemic juvenile arthritis. Rev Rhum (Engl Ed) 1996;63:153-70.
34. Pignatti P, Vivarelli M, Meazza C, Rizzolo MG, Martini A, de Benedetti F. Abnormal regulation of interleukin 6 in systemic juvenile idiopathic arthritis. J Rheumatol 2001;28:1670-6.
35. de Benedetti F, Martini A. Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? J Rheumatol 1998;25:203-7.
36. Fishman D, Gaulds G, Jeffery R, et al. The effect of polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998;102:1369-76.
37. Kawashima M, Yamamura M, Taniai M, et al. Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease. Arthritis Rheum 2001;44:550-60.
38. Kawaguchi Y, Terajima H, Harigai M, Kara M, Kamatani N. Interleukin-18 as a novel diagnostic marker and indicator of disease severity in adult-onset Still's disease. Arthritis Rheum 2001;44:1716-7.
39. Maeno N, Takei S, Nomura Y, Imanaka H, Hokonohara M, Miyata K. Highly elevated serum levels of interleukin-18 in systemic juvenile idiopathic arthritis but not in other juvenile idiopathic arthritis subtypes or in Kawasaki disease: comment on the article by Kawashima, et al. Arthritis Rheum 2002;46:2539-41.
40. de Benedetti F, Pignatti P, Massa M, Sartirara P, Ravelli A, Martini A. Circulating levels of interleukin-1 and of interleukin-1 receptor antagonist in systemic juvenile rheumatoid arthritis. Clin Exp Rheumatol 1995;13:669-84.
41. de Benedetti F, Robbioni P, Massa M, Viola S, Albani S, Marini A. Serum interleukin 6 levels and joint involvement in polyarticular and pauciarticular juvenile rheumatoid arthritis. Clin Exp Rheumatol 1992;10:493-8.
42. Rooney M, David J, Symons J, DiGiovine F, Varsani H, Woo P. Inflammatory cytokine responses in juvenile chronic arthritis. Br J Rheumatol 1995;34:454-60.
43. Iwamoto M, Nara H, Hirata D, et al. Dramatic improvement of intractable adult-onset Still's disease by intravenous humanized anti-interleukin 6 receptor antibody (MRA) [abstract]. Arthritis Rheum 2001;44 Suppl:S118.
44. Yokota S, Miyamae T, Imagawa T, et al. Long-term therapeutic efficacy of humanized anti-IL-6-receptor antibody for systemic juvenile idiopathic arthritis [abstract]. Arthritis Rheum 2002;46 Suppl:S479.
45. Yokata S, Miyamae T, Imagawa T, et al. Phase II trial of anti-IL-6 receptor antibody (MRA) for children with systemic-onset juvenile idiopathic arthritis [abstract]. Arthritis Rheum 2003;48 Suppl:S429.
46. Irigoyen PI, Olson J, Hom C, Ilowite NT. Treatment of systemic onset juvenile rheumatoid arthritis with anakinra [abstract]. Arthritis Rheum 2004;50 Suppl:S437.
47. Henrickson M. Efficacy of anakinra in refractory systemic arthritis [abstract]. Arthritis Rheum 2004;50 Suppl:S438.
48. de Benedetti F, Pignatti P, Massa M, et al. Soluble TNF receptor levels reflect coagulation abnormalities in systemic juvenile chronic arthritis. Br J Rheumatol 1997;36:581-8.
49. Yilmaz M, Kendirli SG, Altinatas D, Bingol G, Antmen B. Cytokine levels in serum of patient with juvenile rheumatoid arthritis. Clin Rheumatol 2001;20:30-5.
50. Ou LS, See LC, Wu CJ, Kao CC, Lin YL, Huang JL. Association between serum inflammatory cytokines and disease activity in juvenile idiopathic arthritis. Clin Rheumatol 2002;21:52-6.